Controversies in Allergy: The potential role of biologics as first line therapy in eosinophilic disorders.

Dellon, Evan S; Simon, Dagmar; Wechsler, Michael E (2022). Controversies in Allergy: The potential role of biologics as first line therapy in eosinophilic disorders. The journal of allergy and clinical immunology. In practice, 10(5), pp. 1169-1176. Elsevier 10.1016/j.jaip.2022.01.043

[img]
Preview
Text
1-s2.0-S2213219822001283-main.pdf - Accepted Version
Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND).

Download (1MB) | Preview

With advances in understanding the role of eosinophils in disease pathogenesis, particularly in the airways, gastrointestinal (GI) tract, and skin, targeting eosinophils or the cytokines that lead to their production, activation, and survival has become an increasingly pursued therapeutic approach. Newly developed biologic agents target eosinophils directly, other cells interacting with or activating eosinophils, or cytokines in the Type 2 inflammatory pathway with specific antibodies. Current treatment paradigms reserve therapy with biologics for patients refractory to or intolerant of corticosteroids or immunosuppressants. Given accumulating data for safety and efficacy of these biologics, however, there is the question of whether targeted treatments should be used earlier in the treatment algorithm. In this article, we discuss the pros and cons of using biologics as first-line therapy for eosinophilic diseases of the airways, GI tract, and skin. We highlight emerging biologic agents and future directions for research, as well as a rationale for the early use of some biologics to prevent tissue damage, disease progression, and organ dysfunction in selected conditions.

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Dermatology

UniBE Contributor:

Simon, Dagmar

Subjects:

600 Technology > 610 Medicine & health

ISSN:

2213-2198

Publisher:

Elsevier

Language:

English

Submitter:

Pubmed Import

Date Deposited:

21 Feb 2022 15:42

Last Modified:

14 Feb 2023 00:25

Publisher DOI:

10.1016/j.jaip.2022.01.043

PubMed ID:

35167955

Uncontrolled Keywords:

asthma atopic dermatitis eosinophilic esophagitis eosinophilic gastrointestinal disease eosinophilic granulomatosis with polyangiitis hypereosinophilic syndrome therapuetics

BORIS DOI:

10.48350/165796

URI:

https://boris.unibe.ch/id/eprint/165796

Actions (login required)

Edit item Edit item
Provide Feedback